Parallel Bio created a human 'immune system in a dish' to discover drugs and immunotherapies more likely to work in patients.
Location: United States, California, Los Angeles
Employees: 1-10
Total raised: $25.3M
Investors 9
| Date | Name | Website |
| - | MarsBio | marsbio.vc |
| 22.07.2025 | AIX Ventur... | aixventure... |
| 21.07.2021 | Y Combinat... | ycombinato... |
| - | Undeterred... | undeterred... |
| 31.12.2024 | Refactor C... | refactor.c... |
| 09.10.2022 | Breakout V... | breakout.v... |
| - | Axial VC | axialvc.co... |
| - | Immeasurab... | immeasurab... |
| - | Kilo Ventu... | kilo.vc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 23.06.2025 | Series A | $21M | - |
| 26.12.2022 | Seed | $4.3M | - |
Mentions in press and media 10
| Date | Title | Description |
| 24.06.2025 | Parallel Bio Secures $21 Million to Revolutionize Drug Discovery | In the bustling world of biotechnology, a new player is making waves. Parallel Bio, a Cambridge-based company, has just raised $21 million in Series A funding. This infusion of capital is not just a financial boost; it’s a lifeline for inno... |
| 23.06.2025 | Parallel Bio: $21 Million Series A Raised For Advancing Human-First Drug Discovery | Parallel Bio, a company pioneering human-first drug discovery, announced it has raised $21 million in Series A funding, led by AIX Ventures. The funding round attracted prominent leaders in AI and biotech, including new investors Amplo and ... |
| 12.06.2025 | Parallel Bio Raises $21M in Series A Funding | Parallel Bio, a Cambridge, MA-based biotech company, raised $21M in Series A funding. The round was led by AIX Ventures, with participation from Amplo and Marc Benioff, founder and CEO of Salesforce, and existing investors Metaplanet, Humba... |
| 26.12.2022 | Parallel Bio Secures $4.3 Million Seed Round to Accelerate Drug Discovery through Human Immune System in a Dish | Parallel Bio, a biotech company unlocking the human body’s own power to cure disease, unveiled $4.3 million in seed funding. The investment capital has enabled it to prove the viability of its immune-system-in-a-dish platform and accelerate... |
| 23.12.2022 | Cambridge-based biotech startup Parallel Bio raises USD 4.3 million in seed funding | CAMBRIDGE, Massachusetts— to harness the human body’s power to cure disease, Parallel Bio announced USD 4.3 million in seed funding. The investment capital has allowed it to demonstrate the viability of its immune-system-in-a-dish platform ... |
| 21.12.2022 | Parallel Bio Raises $4.3M in Seed Funding | Parallel Bio, a Cambridge, MA-based biotech company, raised $4.3M in Seed funding. The round was led by Refactor Capital, with participation from Y Combinator Jeff Dean, Breakout Ventures. The company intends to use the funds to accelerate ... |
| 20.12.2022 | Parallel Bio Nabs $4.3M Seed Financing Round | CAMBRIDGE, MA, Parallel Bio, a biotech company unlocking the human body's own power to cure disease, today unveiled $4.3 million in seed funding. >> Click here for more funding data on Parallel Bio >> To export Parallel Bio ... |
| 01.09.2021 | Here are all the companies from Day 2 of Y Combinator’s Summer 2021 Demo Day | Welcome back to TechCrunch’s continuing coverage of Y Combinator’s Summer 2021 Demo Day! This is Day Two. If you haven’t caught up yet on what happened during the first day, you can read our recap of all the presenting companies here, our f... |
| - | Parallel Bio | “Using the immune system to cure disease. Parallel Bio uses a human immune system in a dish and AI to discover drugs more likely to work in patients.” |
| - | Parallel Bio | “Parallel Bio” |